Search Results

You are looking at 91 - 100 of 438 items for :

Clear All
Full access

1 or 2 toxicities included nausea, anorexia, dysphagia, dehydration, esophagitis, fatigue, constipation, and pain. Grade 3 toxicities included nausea, hyperglycemia, anemia, and leukopenia. One patient had grade 4 toxicity of hyponatremia. One

Full access

Daniel C. McFarland, Heather Polizzi, John Mascarenhas, Marina Kremyanskaya, Jimmie Holland and Ronald Hoffman

assessment of MPN-related symptom burden was captured using the Brief Fatigue Inventory (BFI) and the Functional Assessment of Cancer Therapy-Anemia (FACT-An). The most common symptoms were significant fatigue (81%), pruritus (53%), night sweats (49%), bone

Full access

Arti Hurria, Tanya Wildes, Sarah L. Blair, Ilene S. Browner, Harvey Jay Cohen, Mollie deShazo, Efrat Dotan, Barish H. Edil, Martine Extermann, Apar Kishor P. Ganti, Holly M. Holmes, Reshma Jagsi, Mohana B. Karlekar, Nancy L. Keating, Beatriz Korc-Grodzicki, June M. McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Hope S. Rugo, Randall W. Rupper, Rebecca A. Silliman, Derek L. Stirewalt, William P. Tew, Louise C. Walter, Alva B. Weir III, Mary Anne Bergman and Hema Sundar

, delirium, depression, distress, osteoporosis, falls, fatigue, and frailty are some of the most common syndromes in older patients with cancer. 93 Dementia and delirium are 2 of the most common causes of cognitive impairment. 94 Older patients with cancer

Full access

Arti Hurria, Ilene S. Browner, Harvey Jay Cohen, Crystal S. Denlinger, Mollie deShazo, Martine Extermann, Apar Kishor P. Ganti, Jimmie C. Holland, Holly M. Holmes, Mohana B. Karlekar, Nancy L. Keating, June McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Stephen H. Petersdorf, Hope S. Rugo, Rebecca A. Silliman, William P. Tew, Louise C. Walter, Alva B. Weir III and Tanya Wildes

, depression, distress, osteoporosis, falls, fatigue, and frailty are some of the most common syndromes in elderly cancer patients. 97 Elderly patients with cancer experience a higher prevalence of geriatric syndromes compared with those without cancer. In

Full access

Presenter : Sandy Srinivas

-effect profiles,” Dr. Srinivas said. “The most important side effects of these drugs are fatigue, falls, and fractures.” However, the side-effect profiles of the drugs are somewhat different. The risk of fatigue is higher for apalutamide and enzalutamide (27

Full access

Karen E. Kinahan, Sheetal Kircher, Jessica Altman, Alfred Rademaker, John M. Salsman, Aarati Didwania, Bridget O'Brien, Alpa C. Patel and Stacy D. Sanford

– 29 Other literature on the use of BPAs highlight “alert fatigue,” which occurs when providers are inundated with too many BPAs and ignore them or work around them. 30 , 31 There was evidence of alert fatigue in our study based on the providers

Full access

Michael H. Levy, Thomas Smith, Amy Alvarez-Perez, Anthony Back, Justin N. Baker, Susan Block, Shirley N. Codada, Shalini Dalal, Maria Dans, Jean S. Kutner, Elizabeth Kvale, Sumathi Misra, William Mitchell, Todd M. Sauer, David Spiegel, Linda Sutton, Robert M. Taylor, Jennifer Temel, Roma Tickoo, Susan G. Urba, Carin Van Zyl, Sharon M. Weinstein, Mary Anne Bergman and Jillian L. Scavone

care, including pain, nausea, anxiety, depression, dyspnea, fatigue, psychosocial distress, and loss of appetite. 1 Palliative care in oncology began as hospice and end-of-life care. During the past 20 years, increasing attention has been paid to the

Full access

Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Shaji K. Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Frederic J. Reu, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead and Rashmi Kumar

.2% (3 stringent CRs, 10 VGPRs, 18 PRs). Median response duration was 7.4 months and median time to progression was 3.7 months; the estimated 1-year OS rate was 65%. 22 Adverse events reported included fatigue (39.6%), anemia (33.0%), nausea (29.2%), and

Full access

Michael Levy, Thomas Smith, Amy Alvarez-Perez, Anthony Back, Justin N. Baker, Anna C. Beck, Susan Block, Shalini Dalal, Maria Dans, Thomas R. Fitch, Jennifer Kapo, Jean S. Kutner, Elizabeth Kvale, Sumathi Misra, William Mitchell, Diane G. Portman, Todd M. Sauer, David Spiegel, Linda Sutton, Eytan Szmuilowicz, Robert M. Taylor, Jennifer Temel, Roma Tickoo, Susan G. Urba, Elizabeth Weinstein, Finly Zachariah, Mary Anne Bergman and Jillian L. Scavone

assessed are pain, dyspnea, anorexia, cachexia, nausea, vomiting, constipation, malignant bowel obstruction, fatigue, weakness, asthenia, insomnia, daytime sedation, and delirium. 4 Palliative interventions for these symptoms are discussed individually in

Full access

Renuka Iyer and Kaunteya Reddy

in the placebo group. The most frequent treatment-related adverse events were stomatitis, rash, fatigue, diarrhea, and respiratory infections. Everolimus benefit was due to tumor stabilization in most cases. Promising phase II data prompted another